Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dinaciclib and Ofatumumab in Relapsed/Refractory CLL/SLL/B-PLL
NCT01515176Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2012
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dinaciclib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), B-cell prolymphocytic leukemia (B-PLL), sponsored by National Cancer Institute. Started Jan 2012; status: completed.
02
Drugs
dinaciclib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)B-cell prolymphocytic leukemia (B-PLL)
Beyond the preview
Go deeper on NCT01515176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01515176.